Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022036366 - REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS

Publication Number WO/2022/036366
Publication Date 17.02.2022
International Application No. PCT/US2021/071163
International Filing Date 11.08.2021
IPC
C07K 14/50 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
50Fibroblast growth factor (FGF)
C12N 7/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
CPC
C07K 14/50
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
50Fibroblast growth factors [FGF]
C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Applicants
  • FIGENE, LLC [US]/[US]
Inventors
  • O'HEERON, Pete
  • ICHIM, Thomas
Agents
  • SISTRUNK, Melissa
Priority Data
63/064,53812.08.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS
(FR) RÉDUCTION DE LA COAGULOPATHIE ASSOCIÉE À LA COVID-19 ET D'AUTRES COAGULOPATHIES ASSOCIÉES À UNE INFLAMMATION PAR L'ADMINISTRATION DE FIBROBLASTES
Abstract
(EN) Embodiments of the disclosure include methods and compositions for treatment or reduction in risk of coagulopathy of any kind, including associated with inflammation. In specific embodiments, the coagulopathy is associated with upregulated production of tissue factor in the individual. In specific embodiments, the coagulopathy is in an individual that has SARS-CoV-2 infection or is at risk for having SARS-CoV-2 infection. In specific embodiments, the methods and compositions include fibroblasts, and/or modified fibroblasts, and/or derivatives of fibroblasts, including those fibroblasts exposed to TNF-alpha or one or more other inflammatory agents before activation of the fibroblasts.
(FR) Des modes de réalisation de la divulgation concernent des méthodes et des compositions de traitement ou de réduction du risque de coagulopathie de n'importe quel type, y compris la coagulopathie associée à une inflammation. Dans des modes de réalisation particuliers, la coagulopathie est associée à une production régulée à la hausse du facteur tissulaire chez l'individu. Dans des modes de réalisation particuliers, la coagulopathie concerne un individu atteint d'une infection à SARS-CoV-2 ou présentant un risque d'infection à SARS-CoV-2. Dans des modes de réalisation particuliers, les méthodes et les compositions incluent des fibroblastes, et/ou des fibroblastes modifiés, et/ou des dérivés de fibroblastes, y compris ces fibroblastes exposés au TNF-alpha ou à un ou plusieurs autres agents inflammatoires avant l'activation des fibroblastes.
Latest bibliographic data on file with the International Bureau